Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
847 stopped studies mapped to Malignant Bone Marrow Neoplasm and descendants · 88% state a reason
Over the 847 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT01605981 | Trial Evaluating Nilotinib as Treatment for Newly Diagnosed CML Patients in Accelerated…(MACS1881) | Phase 4 | withdrawn | May 25, 2012 | Novartis Pharmaceuticals | not stated | Not stated |
| NCT02520102 | Open Label Study of Sargramostim Among Patients Receiving Myelosuppressive Induction… | Phase 2 | withdrawn | Aug 11, 2015 | Sanofi | Company has fulfilled post-marketing requirements | Sponsor / business decision |
| NCT02200380 | A Safety and Tolerability Study of CDX-301 With or Without Plerixafor for Stem Cell… | Phase 2 | terminated | Jul 25, 2014 | Celldex Therapeutics | not stated | Not stated |
| NCT01465386 | Bortezomib in Treating Patients With High-Risk Acute Myeloid Leukemia in Remission | Phase 2 | terminated | Nov 4, 2011 | Fred Hutchinson Cancer Center | Closed early due to slow enrollment | Enrollment / accrual |
| NCT01607645 | Decitabine Followed by Idarubicin and Cytarabine in Treating Patients With Relapsed or… | Phase 2 | terminated | May 30, 2012 | Fred Hutchinson Cancer Center | The study was terminated early because there were other competing protocols. | Other (stated, no rule matched) |
| NCT01118013 | Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Malignancies or… | Phase 2 | terminated | May 6, 2010 | Alliance for Clinical Trials in Oncology | not stated | Not stated |
| NCT00363467 | Busulfan Monotherapy as Conditioning for Autologous Hematopoietic Progenitor Cell… | N/A | terminated | Aug 15, 2006 | H. Lee Moffitt Cancer Center and Research Institute | Low accrual | Enrollment / accrual |
| NCT02086487 | Efficacy and Safety Assessment of NIlotinib in CML Patients With Suboptimal Response on…(NISRI) | Phase 4 | terminated | Mar 13, 2014 | King Abdullah International Medical Research Center | Because of many unseen obstacles resulted in poor accrual, study is terminated. | Enrollment / accrual |
| NCT01749111 | Comparison Between Cyclophosphamide and Combination of Methotrexate + Calcineurin…(CICLODECH) | Phase 3 | terminated | Dec 13, 2012 | Hospital Israelita Albert Einstein | Lack of accrual | Enrollment / accrual |
| NCT01621477 | T-Cell Replete Haploidentical Donor Hematopoietic Stem Cell Plus Natural Killer (NK) Cell… | Phase 2 | terminated | Jun 18, 2012 | St. Jude Children's Research Hospital | Study was terminated in August 2016 due to replacement by a new study. | Other (stated, no rule matched) |
| NCT01843179 | Sulindac for Patients With AML | Phase 2 | withdrawn | Apr 30, 2013 | Massachusetts General Hospital | Lack of Funding | Funding |
| NCT00052598 | Therapeutic Allogeneic Lymphocytes and Aldesleukin in Treating Patients With High-Risk or… | Phase 1 / Phase 2 | terminated | Jan 27, 2003 | Fred Hutchinson Cancer Center | not stated | Not stated |
| NCT00946283 | Lactobacillus in Preventing Infection in Patients Undergoing a Donor Stem Cell Transplant… | N/A | terminated | Jul 24, 2009 | Rutgers, The State University of New Jersey | slow accrual | Enrollment / accrual |
| NCT01709396 | ED-TBI Followed By Allogeneic Stem Cell Transplantation For The Treatment Of Refractory…(ED-TBI) | Phase 2 | suspended | Oct 18, 2012 | Ottawa Hospital Research Institute | initial on hold due to space but now permanently suspended due to futility. | Efficacy / futility |
| NCT01176422 | Telomere and Telomerase | — | withdrawn | Aug 6, 2010 | University of Kansas Medical Center | lack of resources; no patient enrollment | Enrollment / accrual |
| NCT01520805 | Safety and Effectiveness Study of CPI-613 to Treat Refractory or Relapsed Leukemia and… | Phase 2 | withdrawn | Jan 30, 2012 | Cornerstone Pharmaceuticals | not stated | Not stated |
| NCT01073436 | Discontinuation of Imatinib Mesylate in Patients With Chronic-Phase Chronic Myeloid… | — | terminated | Feb 23, 2010 | University of Michigan Rogel Cancer Center | Closed prematurely due to low accrual. | Enrollment / accrual |
| NCT00255684 | Fludarabine, Cyclophosphamide, and Total-Body Irradiation Followed by Cyclosporine and… | N/A | terminated | Nov 21, 2005 | University of Rochester | low accrual | Enrollment / accrual |
| NCT02805868 | Siltuximab in Treating Patients With Primary, Post-Polycythemia Vera, or Post-Essential… | Early Phase 1 | withdrawn | Jun 20, 2016 | Northwestern University | Funding | Funding |
| NCT02147873 | Study of Azacitidine With or Without Birinapant in Subjects With MDS or CMMoL | Phase 2 | terminated | May 28, 2014 | TetraLogic Pharmaceuticals | Study terminated due to lack of efficacy | Efficacy / futility |
| NCT02047149 | Evaluating the Safety of Zileuton (Zyflo®) in Combination With Dasatinib (Sprycel®) in… | Phase 1 | terminated | Jan 28, 2014 | University of Massachusetts, Worcester | Low accrual | Enrollment / accrual |
| NCT02528877 | Ruxolitinib Phosphate, Tacrolimus and Sirolimus in Preventing Acute Graft-versus-Host… | Phase 1 | withdrawn | Aug 19, 2015 | City of Hope Medical Center | The study design was revised so a new protocol will be opened. | Other (stated, no rule matched) |
| NCT02146846 | Population Pharmacokinetics of Imatinib in CML Patients in Iran | — | terminated | May 26, 2014 | Kerman University of Medical Sciences | not stated | Not stated |
| NCT02303782 | A Study Assessing tOTX015 in Combination With Azacitidine (AZA) or AZA Single Agent in… | Phase 1 / Phase 2 | withdrawn | Dec 1, 2014 | Oncoethix GmbH, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | not stated | Not stated |
| NCT02115672 | Imatinib and BL-8040 (Novel Anti CXCR4 Antagonist) for Improving Molecular Response in… | Phase 1 / Phase 2 | withdrawn | Apr 16, 2014 | Sheba Medical Center | loss of support | Other (stated, no rule matched) |
| NCT01960387 | Phase II Clofarabine and Cytarabine for Newly Diagnosed Acute Myeloid Leukemia(UPCI 13-066) | Phase 2 | terminated | Oct 10, 2013 | University of Pittsburgh | lack of accrual | Enrollment / accrual |
| NCT01652014 | Single or Double Donor Umbilical Cord Blood Transplant in Treating Patients With… | Phase 2 | withdrawn | Jul 27, 2012 | University of Medicine and Dentistry of New Jersey | Funding unavailable | Funding |
| NCT00004239 | 506U78 in Treating Patients With Hematologic Cancer and Kidney or Liver Impairment | Phase 1 | terminated | Jan 29, 2004 | Alliance for Clinical Trials in Oncology | poor accrual | Enrollment / accrual |
| NCT00185523 | Allogeneic Transplantation for Patients With Acute Leukemia or Chronic Myelogenous… | — | terminated | Sep 16, 2005 | Stanford University | not stated | Not stated |
| NCT01668173 | HSP90 Inhibitor, AUY922, in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia… | Phase 2 | terminated | Aug 17, 2012 | Memorial Sloan Kettering Cancer Center | patient safety | Safety / toxicity |
| NCT02029417 | Omacetaxine Mepesuccinate, Cytarabine, and Decitabine in Treating Older Patients With… | Phase 2 | terminated | Jan 7, 2014 | Roswell Park Cancer Institute | Major revisions needed in study | Other (stated, no rule matched) |
| NCT00579111 | Reduced Intensity Preparative Regimen Followed by Stem Cell Transplant (FAB) | Phase 1 / Phase 2 | terminated | Dec 21, 2007 | Baylor College of Medicine | slow accrual | Enrollment / accrual |
| NCT00578539 | T-Reg Cell Kinetics, Stem Cell Transplant, REGALE(REGALE) | N/A | terminated | Dec 21, 2007 | Baylor College of Medicine | not stated | Not stated |
| NCT02663648 | Cell Cycle Regulatory Gene Study in Patients With Myeloproliferative Disorders | — | withdrawn | Jan 26, 2016 | Shandong University | No eligible patient was enrolled. | Enrollment / accrual |
| NCT00510289 | Sorafenib in Myelodysplastic Syndrome | Phase 2 | terminated | Aug 1, 2007 | Duke University | Early closure of study due to poor response | Other (stated, no rule matched) |
| NCT02221505 | Phase 1 Study of LOP628 in Adult Patients With cKit-positive Solid Tumors and Acute… | Phase 1 | terminated | Aug 20, 2014 | Novartis Pharmaceuticals | not stated | Not stated |
| NCT01573247 | Safety Study of AKN-028 in Patients With Acute Myelogenous Leukemia | Phase 1 / Phase 2 | terminated | Apr 9, 2012 | Akinion Pharmaceuticals AB | During the study two patients have experienced serious liver events related to AKN-028. The… | Other (stated, no rule matched) |
| NCT01455025 | Study in Plerixafor and Granulocyte-colony Stimulating Factor Patients With Relapse Acute…(PRIMAL) | Phase 1 | terminated | Oct 19, 2011 | French Innovative Leukemia Organisation | no recruitment on time | Enrollment / accrual |
| NCT00664677 | Phase 1 Study of Terameprocol (EM-1421) in Patients With Leukemia | Phase 1 | terminated | Apr 23, 2008 | Erimos Pharmaceuticals | Funding constraints | Funding |
| NCT00324077 | Phase I Study of Dasatinib (BMS-354825) and Imatinib in Subjects With Chronic Myeloid… | Phase 1 | withdrawn | May 10, 2006 | Bristol-Myers Squibb | Insufficient Enrollment | Enrollment / accrual |
| NCT00349518 | Study of Dasatinib in Imatinib Resistant or Intolerant Subjects With Chronic or Advanced… | Phase 2 / Phase 3 | withdrawn | Jul 7, 2006 | Bristol-Myers Squibb | not stated | Not stated |
| NCT00660036 | Phase I/II Study of Mitoxantrone, Etoposide and Gemtuzumab Ozogamicin for Acute Myeloid… | Phase 1 | terminated | Apr 17, 2008 | University of Pittsburgh | due to new safety information | Safety / toxicity |
| NCT00630994 | Low-Dose Decitabine in Treating Patients With Symptomatic Myelofibrosis | Phase 2 | terminated | Mar 7, 2008 | Mayo Clinic | Stopped due to slow accrual | Enrollment / accrual |
| NCT01067274 | ALFA-0703 Study in Older Patients With Acute Myeloblastic Leukemia (AML)(ALFA-0703) | Phase 3 | withdrawn | Feb 11, 2010 | Acute Leukemia French Association | Study abandoned | Other (stated, no rule matched) |
| NCT00866281 | A Study of the Safety and Preliminary Efficacy of Oral Midostaurin (PKC412) in Relapsed… | Phase 1 / Phase 2 | terminated | Mar 20, 2009 | Novartis Pharmaceuticals | Despite considerable efforts to boost recruitment during the final year of the study, no new… | Enrollment / accrual |
| NCT01880437 | A Study of Vismodegib in Patients With Relapsed/Refractory Acute Myelogenous Leukemia and… | Phase 2 | terminated | Jun 19, 2013 | Hoffmann-La Roche | not stated | Not stated |
| NCT01169753 | Nuvigil in Treatment of Cancer-Related Fatigue in Chronic Myeloid Leukemia Patients | N/A | terminated | Jul 26, 2010 | M.D. Anderson Cancer Center | Slow Enrollment | Enrollment / accrual |
| NCT01624701 | Clinical Ex Vivo Expansion of Human Umbilical Cord Blood Stem and Progenitor Cells | Phase 1 / Phase 2 | terminated | Jun 21, 2012 | Singapore General Hospital | Funding expired | Funding |
| NCT02034227 | Safety, Tolerability Study of SG2000 in the Treatment of Advanced Chronic Lymphocytic… | Phase 1 / Phase 2 | terminated | Jan 13, 2014 | Spirogen | not stated | Not stated |
| NCT01211691 | Study of KB004 in Subjects With Hematologic Malignancies (Myelodysplastic Syndrome, MDS,… | Phase 1 / Phase 2 | suspended | Sep 29, 2010 | Humanigen, Inc. | KaloBios to Wind Down Operations | Other (stated, no rule matched) |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Apr 20, 2017source: clinicaltrials